[New] Syngene and Bristol Myers Squibb extend their collaboration through 2035, integrating infrastructure and automation to accelerate long-term drug development.
Pharmaceutical Technology
[New] Google-backed Isomorphic Labs, often cited as a flagship of AI-first drug discovery, now expects its first clinical trials to begin by the end of 2026, later than initially anticipated.
Labiotech UG
[New] The proposal to lower drug pricing will help open up conversations about requiring hospitals and providers to slash their prices - which can be a top driver of health insurer premiums.
Health Care News for Insurance Brokers | J&R Report
[New] The pharmaceutical industry has opposed Trump's most-favored-nation push, arguing that it could weaken the dominance of the U.S. in biotech innovation and reduce future investment into novel treatments.
Health Care News for Insurance Brokers | J&R Report
[New] In 2026, we will see changes with how drugs are developed as pharmaceutical companies increasingly embrace new approach methodologies to manage toxicology risk.
Drug Discovery News Magazine
[New] 2026 will see the emergence of AI-native digital CROs that collapse drug discovery timelines by months, even years, by replacing physical experiments with virtual ones while creating an opportunity to reshore drug discovery and strengthen U.S. competitiveness.
Bessemer Venture Partners
[New] The Inflation Reduction Act is reshaping U.S. drug pricing by allowing Medicare to negotiate prices on high-expenditure, single-source drugs beginning in 2026, expanding to 60 drugs by 2030.
Insight Global
[New] While software automation has been well established in pharmaceutical workflows, 2026 will mark a turning point for physical automation in the corporate life sciences environment.
Digital Health Technology News
[New] Many pharmaceutical manufacturers, including Novo Nordisk, Astra Zeneca, Merck, Eli Lilly/BI, Takeda, Johnson & Johnson, Sanofi, and Intarcia Therapeutics, have late-stage pipeline products or recently marketed products that could significantly strengthen their portfolios.
Pharmacy Times
[New] The Food and Drug Administration has signaled that it plans to make approval of the influenza vaccine more difficult, so we may see less availability or no availability of flu vaccines as soon as next year.
Think Global Health
[New] Colombia will continue to work with the United States to fight drug trafficking using Washington's intelligence and technology.
Just Security
[New] CMS will negotiate directly with pharmaceutical manufacturers of GLP-1 drugs for lower net prices, out-of-pocket limits and standardized coverage criteria.
Forbes
[New] The Great Healthcare Plan will slash prescription drug prices, reduce insurance premiums, hold big insurance companies accountable, and maximize price transparency in the American healthcare system.
Healthcare Dive
[New] As pharmaceutical production continues to scale globally, aseptic packaging will remain a vital solution ensuring patient safety, regulatory compliance, and extended product stability across international distribution channels.
openpr
[New] High interest in drug development for oncology, cardiovascular and metabolic diseases, such as obesity and diabetes, are expected to continue in 2026, in addition to modalities such as antibody drug conjugates, radiopharmaceuticals and multi-specific antibodies.
Pharmaceutical Technology
[New] Price controls will cut prescription drug prices 57% to 75% among the most expensive 250 drugs that form the base of U.S. profits.
Journal of Oncology Navigation & Survivorship
[New] Understanding whether biosimilar competition lowers OOP spending for patients with Medicare may offer insights into whether competition has improved access to biologic medications, which could lead to improved adherence and patient outcomes.
PubMed Central (PMC)
[New] FDA's focus on drug pricing may bring opportunities for manufacturers that have room to negotiate and want to gain a regulatory advantage.
Skadden Arps Slate Meagher & Flom LLP
[New] AI takes center stage in drug development: In 2026, AI will shift from a supportive role to an essential, integrated part of drug creation.
Pubs - Bio-IT World
[New] 2026 will feel less like a slow-pipelines world and more like a smart-pipelines world: In 2026, expect the transformation of drug development from a predominantly human-driven, sequential process into a continuously learning, agentic-AI-supported pipeline.
Pubs - Bio-IT World
[New] Agentic AI systems will compress drug development timelines from over a decade to mere months, whilst the World Economic Forum projects that biology-computation convergence will add $4 trillion in value creation.
Blue Ocean Media
[New] Eli Lilly expects an FDA approval in March for oral orforglipron, which the FDA already tapped for its new National Priority Voucher program to speed drug approvals.
PharmaVOICE
Last updated: 27 January 2026
Hi,
Would you like a quick online demo of our service from an experienced member of our team?
